News & Blog

PTC Therapeutics Announces FDA Acceptance and Priority Review for Vatiquinone NDA for the Treatment of Children and Adults with Friedreich’s Ataxia

February 2025 – Advocacy Newsletter Copy

Job Posting: Development Manager (Major Gifts)

Job Posting: Communications & Social Media Coordinator 

Letter to the FA Community from Astellas Pharma

Webinar Recording: PTC Therapeutics Vatiquinone Program January 2025 Update

Janaury 2025 – Advocacy Newsletter

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich’s Ataxia

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Press Release & Community Letter: Solid Biosciences Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich’s Ataxia

December 2024 – Advocacy Newsletter

PTC Therapeutics Announces Vatiquinone NDA Submission to FDA for the Treatment of Children and Adults Living with Friedreich’s Ataxia